Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/yupiq26BJA https://t.co/KDF394SC30

Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg

Metformin Lowers Gout Risk in Pre-Diabetes A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout. https://t.co/IQ1Z7rhhp1 https://t.co/vYKBKsWh0y

Lupus Research Alliance Grants for Lupus Innovation The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). https://t.co/nAlpFyiyUO https://t.co/Rj2JzmmhHO https://t.co/8IG9EkyMad

Gangsin: 갱신 Korean: refresh, renew, updated Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them https://t.co/92tu3de4Ja https://t.co/ePGshN9t51 https://t.co/shdaov1ZPf

JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits - Dx algorithm - Pathophys - Rx options - Alternative Rx https://t.co/epiP8Yi1Oz https://t.co/GsORbADJZy https://t.co/K7Q6Yrx1yI

Hypertension not associated with High NSAID Doses in AxSpA At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs. https://t.co/4XLr01wwo1 https://t.co/hdBYec6wmd

2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk

No Great Options for Treating VEXAS For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO. https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw

ACR Website to Support PCPs The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients. https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt